Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial

Blood (2023) 142 (Supplement 1): 76.

https://doi.org/10.1182/blood-2023-188904

Published: 2023

Journal Articles

Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 3329–3332.

https://doi.org/10.1182/blood-2022-166937

Published: 2022

Journal Articles

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

Ing S Tiong, Devendra Hiwase, Emad Uddin Abro, Ashish Bajel, Emma Palfreyman, Sun Loo, Shaun Fleming, Chun Yew Fong, Tse-Chieh Teh, Adam Ivey, Andrew H Wei

Blood (2022) 140 (Supplement 1): 1453–1455.

https://doi.org/10.1182/blood-2022-163041

Published: 2022

Journal Articles

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

Ing S Tiong, Sun Loo, Emad Uddin Abro, Devendra Hiwase, Shaun Fleming, Ashish Bajel, Emma Palfreyman, Chun Yew Fong, Tse-Chieh Teh, Adam Ivey, Andrew H. Wei

Blood (2021) 138 (Supplement 1): 1261.

https://doi.org/10.1182/blood-2021-152583

Published: 2021

Journal Articles

A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Blood (2021) 138 (Supplement 1): 3675.

https://doi.org/10.1182/blood-2021-147335

Published: 2021

Journal Articles

Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 2648.

https://doi.org/10.1182/blood-2019-123899

Published: 2019

Journal Articles

Combined BCL-2 and HDAC Targeting Has Potent and TP53 Independent Activity in AML

Jessica M Salmon, PhD, Giovanna Pomilio, Donia M Moujalled, PhD, Sarah Macraild, Charis E Teh, PhD, Sewa Riajl, PhD, Adam Ivey, BSc, MSc, PhD, Tse-Chieh Teh, MD, Paul G Ekert, Laurence Kraus-Berthier, Ioana Kloos, Marie Schoumacher, Daniel Gray, Andrew H Wei, MBBS, PhD

Blood (2018) 132 (Supplement 1): 1426.

https://doi.org/10.1182/blood-2018-99-117403

Published: 2018

Journal Articles

Bortezomib Yields High Response Rates in Antibody-Mediated Autoimmune Hematological Diseases Refractory to Conventional Immunosuppression

Sumita Ratnasingam, MBBS, Patricia A. Walker, MBBS, Huy Tran, MBBS, Zane Kaplan, MD, James David McFadyen, MD, Huyen Tran, MD, Tse-Chieh Teh, MD, Erica M. Wood, MD, John V. Catalano, MD, Stephen Opat, MBBS, Jake Shortt, MD

Blood (2015) 126 (23): 3457.

https://doi.org/10.1182/blood.V126.23.3457.3457

Published: 2015

Journal Articles

Inositol polyphosphate 4-phosphatase II (INPP4B) is associated with chemoresistance and poor outcome in AML

Sewa Rijal, Shaun Fleming, Nik Cummings, Natalie K. Rynkiewicz, Lisa M. Ooms, Nhu-Y. N. Nguyen, Tse-Chieh Teh, Sharon Avery, Julie F. McManus, Anthony T. Papenfuss, Catriona McLean, Mark A. Guthridge, Christina A. Mitchell, Andrew H. Wei

Blood (2015) 125 (18): 2815–2824.

https://doi.org/10.1182/blood-2014-09-603555

Published: 2015

Includes: Supplemental data

Journal Articles

Eradication of Acute Myeloid Leukemia Is Enhanced By Combined Bcl-2 and Mcl-1 Targeting

Tse-Chieh Teh, MBBS, FRACP, FRCPA, Nhu-Y Nguyen, PhD, Stefan Glaser, PhD, Donia Moujalled, PhD, Giovanna Pomilio, David CS Huang, Mark Guthridge, Andrew H Wei, MBBS, PhD

Blood (2014) 124 (21): 988.

https://doi.org/10.1182/blood.V124.21.988.988

Published: 2014

Journal Articles

Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription

Blood (2013) 122 (5): 738–748.

https://doi.org/10.1182/blood-2012-08-447441

Published: 2013

Includes: Supplemental data

NARROW

Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial

Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia

A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML)

Combined BCL-2 and HDAC Targeting Has Potent and TP53 Independent Activity in AML

Bortezomib Yields High Response Rates in Antibody-Mediated Autoimmune Hematological Diseases Refractory to Conventional Immunosuppression

Inositol polyphosphate 4-phosphatase II (INPP4B) is associated with chemoresistance and poor outcome in AML

Eradication of Acute Myeloid Leukemia Is Enhanced By Combined Bcl-2 and Mcl-1 Targeting

Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only